Jin Asano

428 total citations
11 papers, 318 citations indexed

About

Jin Asano is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Jin Asano has authored 11 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in Jin Asano's work include Peptidase Inhibition and Analysis (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Bone health and treatments (2 papers). Jin Asano is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Multiple Myeloma Research and Treatments (3 papers) and Bone health and treatments (2 papers). Jin Asano collaborates with scholars based in Japan. Jin Asano's co-authors include Ken-ichi Kitazoe, Toshio Matsumoto, Toshihiro Hashimoto, Masahiro Abe, Shuji Ozaki, Hironobu Shibata, Daisuke Inoue, Etsuko Sekimoto, Tomoko Hara and Shinsuke Kido and has published in prestigious journals such as Blood, International Journal of Hematology and Virus Genes.

In The Last Decade

Jin Asano

9 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jin Asano Japan	4	215	193	157	20	19	11	318
Clive Buckle United Kingdom	6	180 0.8×	125 0.6×	157 1.0×	25 1.3×	23 1.2×	9	279
Etsuko Sekimoto Japan	5	197 0.9×	180 0.9×	159 1.0×	16 0.8×	21 1.1×	21	318
E Martella Italy	4	128 0.6×	100 0.5×	97 0.6×	8 0.4×	15 0.8×	8	207
Magdalena Hinterbrandner Switzerland	6	145 0.7×	101 0.5×	105 0.7×	26 1.3×	21 1.1×	7	270
Pauline Huyghe France	4	121 0.6×	314 1.6×	262 1.7×	17 0.8×	86 4.5×	9	389
Annegret Rosemann Germany	6	151 0.7×	198 1.0×	104 0.7×	16 0.8×	33 1.7×	6	379
Sabrina Pechtel Germany	9	72 0.3×	216 1.1×	102 0.6×	13 0.7×	81 4.3×	12	292
Jean‐Valère Malfuson France	8	50 0.2×	143 0.7×	142 0.9×	11 0.6×	42 2.2×	15	250
Manuela Gambella Italy	8	116 0.5×	193 1.0×	181 1.2×	12 0.6×	24 1.3×	13	283

Countries citing papers authored by Jin Asano

Since Specialization

Citations

This map shows the geographic impact of Jin Asano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Asano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Asano more than expected).

Fields of papers citing papers by Jin Asano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Asano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Asano. The network helps show where Jin Asano may publish in the future.

Co-authorship network of co-authors of Jin Asano

This figure shows the co-authorship network connecting the top 25 collaborators of Jin Asano. A scholar is included among the top collaborators of Jin Asano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin Asano. Jin Asano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Asano, Jin, et al.. (2014). Effects of Immunosuppressive Therapy in a Patient with Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria (AA-PNH) Syndrome during Ongoing Eculizumab Treatment. Internal Medicine. 53(2). 125–128. 3 indexed citations

2.

Hayashi, Tsutomu, et al.. (2007). . Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 16(1). 66–73.

3.

Ozaki, Shuji, Osamu Tanaka, Shiro Fujii, et al.. (2007). Therapy with Bortezomib plus Dexamethasone Induces Osteoblast Activation in Responsive Patients with Multiple Myeloma. International Journal of Hematology. 86(2). 180–185. 42 indexed citations

4.

Kagawa, Kumiko, Masahiro Abe, Shiro Fujii, et al.. (2007). Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.. Blood. 110(11). 244–244.

5.

Asano, Jin, Masahiro Abe, Shiro Fujii, et al.. (2007). The Serine/Threonine Kinase Pim-2 Is a Novel Anti-Apoptotic Mediator in Myeloma Cells.. Blood. 110(11). 243–243. 1 indexed citations

6.

Takeuchi, Kyoko, Masahiro Abe, Asuka Oda, et al.. (2006). SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.. Blood. 108(11). 3479–3479. 2 indexed citations

7.

Kitazoe, Ken-ichi, Masahiro Abe, Kumiko Kagawa, et al.. (2006). Emerging of Valproic Acid as an Anti-Myeloma Agent.. Blood. 108(11). 3482–3482. 1 indexed citations

8.

Oshima, Takashi, Masahiro Abe, Jin Asano, et al.. (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 106(9). 3160–3165. 256 indexed citations

9.

Ozaki, Shuji, Etsuko Sekimoto, Yoichi Tanaka, et al.. (2005). Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).. Blood. 106(11). 3388–3388. 1 indexed citations

10.

Oshima, Takashi, Masahiro Abe, Jin Asano, et al.. (2004). Myeloma Cells Suppress Osteoblast Differentiation by Secreting a Soluble Wnt Inhibitor, sFRP-2.. Blood. 104(11). 2356–2356. 6 indexed citations

11.

Sone, Saburo, et al.. (1997). Functional Analysis of vif Genes Derived from Various Primate Immunodeficiency Viruses. Virus Genes. 14(3). 195–200. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact